Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, commonly known as Sobi, is an international biopharmaceutical company dedicated to rare diseases. The company organizes its operational reporting and commercial strategy around two key therapeutic areas: Hematology and Immunology. Its product portfolio features biopharmaceuticals for hemophilia care, severe auto-inflammatory syndromes, and specialty metabolic disorders. Revenues are generated through commercial sales of prescription orphan drugs to hospitals, specialty pharmacies, and healthcare systems. The enterprise holds a market-leading European and global position in specialized hematology and niche immunology therapies. Swedish Orphan Biovitrum is headquartered in Stockholm, Sweden, and its shares are traded on Nasdaq Stockholm.
88 of the funds FundTelligence covers report a position in Swedish Orphan Biovitrum.
- Legal name
- Swedish Orphan Biovitrum AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 88
Funds holding Swedish Orphan Biovitrum
- Lannebo Sweden All Cap — Lannebo · 5.69 % (full portfolio disclosed, June 2026)
- Aktie-Ansvar Sverige — Aktie-Ansvar · 4.05 % (full portfolio disclosed, June 2026)
- Carnegie All Cap — Carnegie · 3.75 % (full portfolio disclosed, June 2026)
- Lannebo Sverige Plus — Lannebo · 3.67 % (full portfolio disclosed, June 2026)
- Lannebo Sverige — Lannebo · 3.66 % (full portfolio disclosed, June 2026)
- PriorNilsson Sverige Aktiv — PriorNilsson · 3.07 % (full portfolio disclosed, June 2026)
- Cicero Yield — Cicero Fonder · 2.96 % (full portfolio disclosed, June 2026)
- Simplicity Norden — Simplicity · 2.8 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 88 funds holding it.